Restricting glutamine or glutamine-dependent purine and pyrimidine syntheses promotes human t cells with high FOXP3 expression and regulatory properties

Journal of Immunology

Volumn 196, Issue 9, 2016, Pages 3618-3630

  Metzler, Barbara ^a   Gfeller, Patrick ^a   Guinet, Elisabeth ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; PURINE; PYRIMIDINE; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NUCLEOTIDE METABOLISM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GLUTAMATE-AMMONIA LIGASE; GLUTAMINE; HUMANS; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PURINES; PYRIMIDINES;

EID: 84974807592     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501756     Document Type: Article

References (55)

1. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20-21.
2. Bluestone, J. A., and H. Bour-Jordan. 2012. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb. Perspect. Biol. 4: a007542.
3. Juvet, S. C., A. G. Whatcott, A. R. Bushell, and K. J. Wood. 2014. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am. J. Transplant. 14: 750-763.
4. +CD252 T cells. J. Clin. Invest. 112: 1437-1443.
5. Gavin, M. A., T. R. Torgerson, E. Houston, P. DeRoos, W. Y. Ho, A. Stray-Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, and A. Y. Rudensky. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103: 6659-6664.
6. +FOXP32 T cells by T-cell receptor stimulation is transforming growth factor-b-ependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
7. MacIver, N. J., R. D. Michalek, and J. C. Rathmell. 2013. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31: 259-283.
8. Pollizzi, K. N., and J. D. Powell. 2014. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14: 435-446.
9. Kraaij, M. D., N. D. Savage, S. W. van der Kooij, K. Koekkoek, J. Wang, J. M. van den Berg, T. H. Ottenhoff, T. W. Kuijpers, R. Holmdahl, C. van Kooten, and K. A. Gelderman. 2010. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 107: 17686-17691.
10. Moraes-Vieira, P. M., E. J. Bassi, R. A. Larocca, A. Castoldi, M. Burghos, A. P. Lepique, F. J. Quintana, R. C. Araujo, A. S. Basso, T. B. Strom, and N. O. Câmara. 2013. Leptin deficiency modulates allograft survival by favoring a Th2 and a regulatory immune profile. Am. J. Transplant. 13: 36-44.
11. Berod, L., C. Friedrich, A. Nandan, J. Freitag, S. Hagemann, K. Harmrolfs, A. Sandouk, C. Hesse, C. N. Castro, H. Bähre, et al. 2014. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 20: 1327-1333.
12. Curi, R., C. J. Lagranha, S. Q. Doi, D. F. Sellitti, J. Procopio, T. C. Pithon-Curi, M. Corless, and P. Newsholme. 2005. Molecular mechanisms of glutamine action. J. Cell. Physiol. 204: 392-401.
13. Newsholme, E. A., B. Crabtree, and M. S. Ardawi. 1985. Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q. J. Exp. Physiol. 70: 473-489.
14. Crawford, J., and H. J. Cohen. 1985. The essential role of L-glutamine in lymphocyte differentiation in vitro. J. Cell. Physiol. 124: 275-282.
15. Carr, E. L., A. Kelman, G. S. Wu, R. Gopaul, E. Senkevitch, A. Aghvanyan, A. M. Turay, and K. A. Frauwirth. 2010. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol. 185: 1037-1044.
16. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 22DDC(T) method. Methods 25: 402-408.
17. Wise, D. R., R. J. DeBerardinis, A. Mancuso, N. Sayed, X. Y. Zhang, H. K. Pfeiffer, I. Nissim, E. Daikhin, M. Yudkoff, S. B. McMahon, and C. B. Thompson. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105: 18782-18787.
18. Thompson, C. B. 2011. Rethinking the regulation of cellular metabolism. Cold Spring Harb. Symp. Quant. Biol. 76: 23-29.
19. Jones, M. E. 1980. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem. 49: 253-279.
20. Grem, J. L., S. A. King, P. J. O'Dwyer, and B. Leyland-Jones. 1988. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Cancer Res. 48: 4441-4454.
21. Mitchell, A. P., and B. Magasanik. 1984. Three regulatory systems control production of glutamine synthetase in Saccharomyces cerevisiae. Mol. Cell. Biol. 4: 2767-2773.
22. Lacoste, L., K. D. Chaudhary, and J. Lapointe. 1982. Derepression of the glutamine synthetase in neuroblastoma cells at low concentrations of glutamine. J. Neurochem. 39: 78-85.
23. Ronzio, R. A., W. B. Rowe, and A. Meister. 1969. Studies on the mechanism of inhibition of glutamine synthetase by methionine sulfoximine. Biochemistry 8: 1066-1075.
24. Berlicki, ?. 2008. Inhibitors of glutamine synthetase and their potential application in medicine. Mini Rev. Med. Chem. 8: 869-878.
25. Krummey, S. M., J. A. Cheeseman, J. A. Conger, P. S. Jang, A. K. Mehta, A. D. Kirk, C. P. Larsen, and M. L. Ford. 2014. High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Am. J. Transplant. 14: 607-614.
26. Alegre, M. L., H. Shiels, C. B. Thompson, and T. F. Gajewski. 1998. Expression and function of CTLA-4 in Th1 and Th2 cells. J. Immunol. 161: 3347-3356.
27. Pandiyan, P., D. Gärtner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, and M. C. Brunner-Weinzierl. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 199: 831-842.
28. Walker, L. S. 2013. Treg and CTLA-4: two intertwining pathways to immune tolerance. J. Autoimmun. 45: 49-57.
29. Klysz, D., X. Tai, P. A. Robert, M. Craveiro, G. Cretenet, L. Oburoglu, C. Mongellaz, S. Floess, V. Fritz, M. I. Matias, et al. 2015. Glutamine-dependent a-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci. Signal. 8: ra97.
30. Quéméneur, L., L. M. Gerland, M. Flacher, M. Ffrench, J. P. Revillard, and L. Genestier. 2003. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J. Immunol. 170: 4986-4995.
31. Colquhoun, A., and E. A. Newsholme. 1997. Aspects of glutamine metabolism in human tumour cells. Biochem. Mol. Biol. Int. 41: 583-596.
32. Evans, M. E., D. P. Jones, and T. R. Ziegler. 2005. Glutamine inhibits cytokineinduced apoptosis in human colonic epithelial cells via the pyrimidine pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G388-G396.
33. Caldwell, M. D. 1989. Local glutamine metabolism in wounds and inflammation. Metabolism 38(8, Suppl 1)34-39.
34. Hulsewé, K. W., R. W. van der Hulst, B. A. van Acker, M. F. von Meyenfeldt, and P. B. Soeters. 2004. Inflammation rather than nutritional depletion determines glutamine concentrations and intestinal permeability. Clin. Nutr. 23: 1209-1216.
35. Chandrasekhar, S., W. W. Souba, and S. F. Abcouwer. 1999. Identification of glucocorticoid-responsive elements that control transcription of rat glutamine synthetase. Am. J. Physiol. 276: L319-L331.
36. Kamei, Y., M. Hattori, Y. Hatazawa, T. Kasahara, M. Kanou, S. Kanai, X. Yuan, T. Suganami, W. H. Lamers, T. Kitamura, and Y. Ogawa. 2014. FOXO1 activates glutamine synthetase gene in mouse skeletal muscles through a region downstream of 39-UTR: possible contribution to ammonia detoxification. Am. J. Physiol. Endocrinol. Metab. 307: E485-E493.
37. van der Vos, K. E., P. Eliasson, T. Proikas-Cezanne, S. J. Vervoort, R. van Boxtel, M. Putker, I. J. van Zutphen, M. Mauthe, S. Zellmer, C. Pals, et al. 2012. Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat. Cell Biol. 14: 829-837.
38. Hedrick, S. M., R. Hess Michelini, A. L. Doedens, A. W. Goldrath, and E. L. Stone. 2012. FOXO transcription factors throughout T cell biology. Nat. Rev. Immunol. 12: 649-661.
39. + T cell fate decisions. J. Immunol. 194: 4615-4619.
40. Peter, C., H. Waldmann, and S. P. Cobbold. 2010. mTOR signalling and metabolic regulation of T cell differentiation. Curr. Opin. Immunol. 22: 655-661.
41. Nicklin, P., P. Bergman, B. Zhang, E. Triantafellow, H. Wang, B. Nyfeler, H. Yang, M. Hild, C. Kung, C. Wilson, et al. 2009. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136: 521-534.
42. Nakaya, M., Y. Xiao, X. Zhou, J. H. Chang, M. Chang, X. Cheng, M. Blonska, X. Lin, and S. C. Sun. 2014. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40: 692-705.
43. Sojka, D. K., A. Hughson, T. L. Sukiennicki, and D. J. Fowell. 2005. Early kinetic window of target T cell susceptibility to CD25+ regulatory T cell activity. J. Immunol. 175: 7274-7280.
44. Hou, T. Z., O. S. Qureshi, C. J. Wang, J. Baker, S. P. Young, L. S. Walker, and D. M. Sansom. 2015. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J. Immunol. 194: 2148-2159.
45. + T cells capable of producing proinflammatory cytokines. Blood 121: 2647-2658.
46. Afzali, B., P. J. Mitchell, F. C. Edozie, G. A. Povoleri, S. E. Dowson, L. Demandt, G. Walter, J. B. Canavan, C. Scotta, B. Menon, et al. 2013. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur. J. Immunol. 43: 2043-2054.
47. + T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
48. + regulatory T cells in humans. Proc. Natl. Acad. Sci. USA 106: 4793-4798.
49. Sanchez Rodriguez, R., M. L. Pauli, I. M. Neuhaus, S. S. Yu, S. T. Arron, H. W. Harris, S. H. Yang, B. A. Anthony, F. M. Sverdrup, E. Krow-Lucal, et al. 2014. Memory regulatory T cells reside in human skin. J. Clin. Invest. 124: 1027-1036.
50. + T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20: 62-68.
51. + T regulatory cells in human autoimmunity: more than a numbers game. J. Immunol. 187: 2061-2066.
52. +CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients. Am. J. Transplant. 6: 2955-2964.
53. + regulatory T cell-frequency in human peripheral-blood mononuclear cells activated by T cell-mitogen. Int. Immunopharmacol. 15: 160-166.
54. Whiteside, T. L. 2014. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin. Biol. Ther. 14: 1411-1425.
55. Hensley, C. T., A. T. Wasti, and R. J. DeBerardinis. 2013. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123: 3678-3684.